Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday. The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use. The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said. In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease. |
U.S. stocks tick down as Apple drags tech sector lowerPioneering zone to be launched in Hunan to propel SinoShanghai makes great strides in improving business environmentNew model reveals seabirds' movement may help analyze animal decisionLuxury brands embrace the Year of the DragonChina launches new satellite for space environment surveyXi Meets Cambodian Prime MinisterNvidia CEO visits BeijingSearches for hotels surge 4 times after ChinaChina launches new Earth observation satellite for environmental monitoring